- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04446806
Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia
A Prospective Single Center Study of Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia
Study Overview
Detailed Description
Adults ages 18-75 with primary acute promyelocytic leukemia.
Design:
The induction therapy with ATRA 25mg/m2/d and ATO 10mg/kg/d should be started as soon as the diagnosis of APL confirmed.
Intravenous dexamethasone at a dose of 5-20 mg daily must be started if the WBC count greater than 5e+9/L (before or during the treatment with ATRA) as prevention or preemptive therapy of DS.
Idarubicin (4-10 mg/m2 /d*3d) and hydroxyurea(1.0-3.0g/d)can be given as leukocyte lowering therapy which may lessen the risk of DS.
When the progression of clinical symptoms of DS with no response to dexamethasone,ATRA must be stopped and ruxolitinib (5-20mg /d) should be administrated to reduce the production of cytokines.
Participants should stay in the hospital during the treatment for about 4 weeks.
The changes of spectrum of cytokines are monitored to discover the potential relationship between the cytokines and the severity of DS.
Participants will visit every 1 months after CR for 3 years.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215000
- Recruiting
- First Affiliated Hospital, Soochow University
-
Contact:
- Qian Wu
- Phone Number: 8613656205608
- Email: 42732890@qq.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis of primary acute promyelocytic leukemia.
- ECOG score≤3.
- Must be able to understand and willing to participate in the study and sign the informed consent.
Exclusion Criteria:
- Refractory/secondary acute promyelocytic leukemia.
- Severe complications such as myocardial infarction, chronic cardiac insufficiency, hepatic failure, renal insufficiency, etc.
- Clinically uncontrolled active infections.
- Malignant tumors with other progresses.
- Ecg: QT interval > 450 ms.
- Allergic to arsenic agent.
- Pregnant or lactating women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
complete remission rate
Time Frame: during the induction treatment
|
complete remission rate after treated by the induction regimen with ATRA and Arsenite
|
during the induction treatment
|
|
incidence and severity of differentiation syndrome
Time Frame: during the induction treatment
|
All symptoms and signs associated to DS should be paid closely attention to.
|
during the induction treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
overall survival
Time Frame: from the day of first patient treatment up to 36 months after the last patient's enrollment
|
from the date of inclusion to date of death, irrespective of cause
|
from the day of first patient treatment up to 36 months after the last patient's enrollment
|
Collaborators and Investigators
Investigators
- Study Chair: Qian Wu, First Affiliated Hospital, Soochow University Suzhou, Jiangsu, China, 215000
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- APL-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.